Treatment of Liposarcoma in Myxoid Liposarcoma
Myxoid liposarcoma (MLS) is a distinct histological subtype of liposarcoma with recognised differences in treatment response compared with other soft tissue sarcoma subtypes. Histological subtype confirmation is central to clinical decision-making in this setting.
This protocol applies to patients with myxoid liposarcoma, a specific soft tissue sarcoma subtype. Among sarcoma subtypes, MLS is one of those that may gain particular benefit from certain treatment approaches, making accurate histological classification an important step before therapy selection.
In advanced myxoid liposarcoma, a specific systemic agent with reported high antitumour activity — and a distinctive, peculiar pattern of tumour response — may be considered. The complete structured regimen, eligibility criteria, evidence grading, and sequencing are available in the full protocol.
References
- Histological types such as MLS, solitary fibrous tumour (SFT), myxofibrosarcoma and extraskeletal myxoid chondrosarcoma gain the greatest benefit from RT.
- A high antitumour activity has been reported especially in MLS, with a peculiar pattern of tumour response.
- Trabectedin is an option in advanced STS in second and further lines of treatment [I, B; ESMO-MCBS v1.1 score: 2].
DOI: 10.1016/j.annonc.2021.07.006
View source ↗